Kad­mon wax­es rhap­sod­ic on cGVHD re­sults as race with Jakafi heats up

A year ago, Kad­mon piqued cau­tious in­ter­est and sent its stock up 20% when it an­nounced pos­i­tive re­sults from a tiny proof-of-con­cept study on a new, chron­ic graft-ver­sus-host-dis­ease treat­ment. Now in­ter­im re­sults are out on the piv­otal, and not just the biotech’s ex­ec­u­tives are gush­ing about it.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.